Formulation of ciprofloxacin hydrochloride loaded biodegradable nanoparticles: Optimization of technique and process variables

Pharmaceutical Development and Technology

Volumn 19, Issue 7, 2014, Pages 891-900

  Mobarak, Doaa H ^a   Salah, Salwa ^a   Elkheshen, Seham A ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b Future University in Egypt   (Egypt)

Author keywords

Ciprofloxacin hydrochloride; Double emulsion; High pressure homogenizer; PLGA nanoparticles; Solvent diffusion

Indexed keywords

CIPROFLOXACIN; NANOPARTICLE; POLYVINYL ALCOHOL; SODIUM CHLORIDE;

ARTICLE; DRUG FORMULATION; DRUG RELEASE; EMULSION; ENCAPSULATION; HYPERBARISM; IN VITRO STUDY; INFRARED RADIATION; PARTICLE SIZE; PRIORITY JOURNAL; ULTRASOUND; X RAY; ZETA POTENTIAL;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DRUG CARRIERS; EMULSIONS; LACTIC ACID; NANOPARTICLES; POLYGLYCOLIC ACID;

EID: 84898741672     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2013.836293     Document Type: Article

References (50)

1. WHO C diseases. WHO | Chronic diseases. World Health Organization. Available from: http://www.who.int/topics/chronic-diseases/en/[last accessed 3 May 2012].
2. Lew D, Waldvogel F. Osteomyelitis. New Engl J Med 1997;336: 999-1007.
3. Haidar R, Der Boghossian A, Atiyeh B. Duration of post-surgical antibiotics in chronic osteomyelitis: empiric or evidence-based? Int J Infect Dis 2010;14:e752-e758.
4. Sheehy SH, Atkins BA, Bejon P, et al. The microbiology of chronic osteomyelitis: prevalence of resistance to common empirical antimicrobial regimens. J infect 2010;60:338-343.
5. Ellington JK, Harris M, Hudson MC, et al. Intracellular Staphylococcus aureus and antibiotic resistance: implications for treatment of staphylococcal osteomyelitis. J Orthop Res 2006;24: 87-93.
6. Jeong Y-I, Na H-S, Seo D-H, et al. Ciprofloxacin-encapsulated poly(DL-lactide-co-glycolide) nanoparticles and its antibacterial activity. Int J Pharm 2008;352:317-323.
7. Nelson JM, Chiller TM, Powers JH, Angulo FJ. Fluoroquinoloneresistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story. Clin Infect Dis 2007;44:977-980.
8. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997;61:377-392.
9. Koort JK, Suokas E, Veiranto M, et al. In vitro and in vivo testing of bioabsorbable antibiotic containing bone filler for osteomyelitis treatment. J Biomed Mater Res A 2006;78:532-540.
10. Castro C, Sánchez E, Delgado A, et al. Ciprofloxacin implants for bone infection. In vitro-in vivo characterization. J Control Rel 2003; 93:341-354.
11. Overbeck JP, Winckler ST, Meffert R, et al. Penetration of ciprofloxacin into bone: a new bioabsorbable implant. J Invest Surg 1995;8:155-162.
12. Dimaio FR, O'Halloran JJ, Quale JM. In vitro elution of ciprofloxacin from polymethylmethacrylate cement beads. J Orthop Res 1994;12:79-82.
13. Calhoun JH, Manring M. Adult osteomyelitis. Infect Dis Clin N Am 2005;19:765-786.
14. Champion JA, Katare YK, Mitragotri S. Particle shape: a new design parameter for micro-and nanoscale drug delivery carriers. J Control Rel 2007;121:3-9.
15. Pal SL, Jana U, Manna PK, et al. Nanoparticle: an overview of preparation and characterization. J Appl Pharm Sci 2011;01: 228-234.
16. Mundargi RC, Babu VR, Rangaswamy V, et al. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Rel 2008;125:193-209.
17. Cevher E, Orhan Z, Sensoy D, et al. Sodium fusidate-poly(D,Llactide-co- glycolide) microspheres: preparation, characterisation and in vivo evaluation of their effectiveness in the treatment of chronic osteomyelitis. J Microencapsul 2007;24:577-595.
18. Prior S, Gander B, Blarer N, et al. In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. Eur J Pharm Sci 2002;15: 197-207.
19. Lecároz C, Blanco-Prieto MJ, Burrell MA, Gamazo C. Intracellular killing of Brucella melitensis in human macrophages with microsphere- encapsulated gentamicin. J Antimicrob Chemother 2006;58: 549-556.
20. Xu Q, Crossley A, Czernuszka JAN. Preparation and characterization of negatively charged poly (lactic-co-glycolic acid) microspheres. J Pharm Sci 2009;98:2377-2389.
21. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Rel 2002;82:105-114.
22. Dong Y, Feng S-S. Poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles prepared by high pressure homogenization for paclitaxel chemotherapy. Int J Pharm 2007;342:208-214.
23. Dillen K, Vandervoort J, Van den Mooter G, Ludwig A. Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles. Int J Pharm 2006;314:72-82.
24. Yu W, Wong J, Chang T. Biodegradable polylactic acid nanocapsules containing ciprofloxacin: preparation and characterization. Artif Cells Blood Substit Immobil Biotechnol 1999;27: 263-278.
25. Dillen K, Vandervoort J, Van den Mooter G, et al. Factorial design, physicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles. Int J Pharm 2004;275:171-187.
26. Sant S, Nadeau V, Hildgen P. Effect of porosity on the release kinetics of propafenone-loaded PEG-g-PLA nanoparticles. J Control Rel 2005;107:203-214.
27. Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. Int J Pharm 1961;50:874-875.
28. Bilati U, Allémann E, Doelker E. Sonication parameters for the preparation of biodegradable nanocapsules of controlled size by the double emulsion method. Pharm Dev Technol 2003;8:1-9.
29. Meng FT, Ma GH, Qiu W, Su ZG. W/O/W double emulsion technique using ethyl acetate as organic solvent: effects of its diffusion rate on the characteristics of microparticles. J Control Rel 2003;91:407-416.
30. Cohen-Sela E, Chorny M, Koroukhov N, et al. A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. J Control Rel 2009;133: 90-95.
31. Lamprecht A, Ubrich N, Pérez MH, et al. Influences of process parameters on nanoparticle preparation performed by a double emulsion pressure homogenization technique. Int J Pharm 2000;196: 177-182.
32. Li X, Xu Y, Chen G, et al. PLGA nanoparticles for the oral delivery of 5-Fluorouracil using high pressure homogenizationemulsification as the preparation method and in vitro/in vivo studies. Drug Dev Ind Pharm 2008;34:107-115.
33. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. J Control Rel 2002;6:319-327.
34. Jafari S, Assadpoor E, He Y, Bhandari B. Re-coalescence of emulsion droplets during high-energy emulsification. Food Hydrocoll 2008;22:1191-1202.
35. Pillai RR, Somayaji SN, Rabinovich M, et al. Nafcillin-loaded PLGA nanoparticles for treatment of osteomyelitis. Biomed Mater (Bristol, England) 2008;3:034114.
36. Yeo Y, Park K. Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Arch Pharmacal Res 2004;27: 1-12.
37. Peltonen L, Aitta J, Hyvönen S, et al. Improved entrapment efficiency of hydrophilic drug substance during nanoprecipitation of poly(l)lactide nanoparticles. AAPS PharmSciTech 2004;5:E16.
38. Péan JM, Venier-Julienne MC, Boury F, et al. NGF release from poly(D,L-lactide-co-glycolide) microspheres. Effect of some formulation parameters on encapsulated NGF stability. J Control Rel 1998;56:175-187.
39. Yu X, Zipp GL, Davidson GW. The effect of temperature and pH on the solubility of quinolone compounds: estimation of heat of fusion. Pharmaceut Res 1994;11:522-527.
40. Rosca ID, Watari F, Uo M. Microparticle formation and its mechanism in single and double emulsion solvent evaporation. J Control Rel 2004;99:271-280.
41. Esmaeili F, Hosseini-Nasr M, Rad-Malekshahi M, et al. Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles. Nanomedicine 2007;3:161-167.
42. Song X, Zhao Y, Hou S, et al. Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm 2008;69:445-453.
43. Musumeci T, Ventura CA, Giannone I, et al. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm 2006;325: 172-179.
44. Mohammadi G, Valizadeh H, Barzegar-Jalali M, et al. Development of azithromycin-PLGA nanoparticles: physicochemical characterization and antibacterial effect against Salmonella typhi. Colloid Surf B-Biointerfaces 2010;80:34-39.
45. Roser M, Fischer D, Kissel T. Surface-modified biodegradable albumin nano-and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm 1998;46:255-263.
46. Kumar G, Sharma S, Shafiq N, et al. Optimization, in vitro-in vivo evaluation, and short-term tolerability of novel levofloxacin-loaded PLGA nanoparticle. J Pharm Sci 2012;101:2165-2176.
47. Leroueil-Le Verger M, Fluckiger L, et al. Preparation and characterization of nanoparticles containing an antihypertensive agent. Eur J Pharm Biopharm 1998;46:137-143.
48. Kim H, Fassihi R. Application of a binary polymer system in drug release rate modulation. 1. Characterization of release mechanism. J Pharm Sci 1997;86:316-322.
49. Ritger P, Peppas N. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J Control Rel 1987;5:37-42.
50. Yu L, Zhang H, Cheng S-X, et al. Study on the drug release property of cholesteryl end-functionalized poly(epsilon-caprolactone) microspheres. J Biomed Mater Res B Appl Biomater 2006;77: 39-46.